Combined autophagy and proteasome inhibition

A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma

Dan T Vogl Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USACorrespondence[email protected]

Edward A Stadtmauer Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA

Kay-See Tan Department of Biostatistics and Epidemiology; University of Pennsylvania; Philadelphia, PA USA

Daniel F Heitjan Department of Biostatistics and Epidemiology; University of Pennsylvania; Philadelphia, PA USA

Lisa E Davis Department of Pharmacy Practice and Pharmacy Administration; University of the Sciences in Philadelphia; Philadelphia, PA USA

Laura Pontiggia Department of Mathematics, Physics and Statistics; University of the Sciences in Philadelphia; Philadelphia, PA USA

Reshma Rangwala Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA

Shengfu Piao Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA

Yunyoung C Chang Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA

Emma C Scott Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA

Thomas M Paul Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA

Charles W Nichols Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA

David L Porter Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA

Janeen Kaplan Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA

Gayle Mallon Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA

James E Bradner Division of Hematologic Neoplasia; Dana-Farber Cancer Institute; Boston, MA USA

Ravi K Amaravadi Abramson Cancer Center; University of Pennsylvania; Philadelphia, PA USA